GlassScriptPhysician profile
Helena Sagalovsky
NPI 1154511335
$7,444.56
in general payments reported to CMS, 2019-2025
55 companies · $1,603 in 2025
The $1,603 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $596 · 2020: $767 · 2021: $869 · 2022: $1,252 · 2023: $1,198 · 2024: $1,159 · 2025: $1,603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,960.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $577.73 | 2019-2025 | Synthroid, Ubrelvy, Viberzi |
| Novartis Pharmaceuticals Corporation | $576.64 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $521.64 | 2020-2025 | Austedo Xr, Austedo Xr |
| Jazz Pharmaceuticals INC. | $496.43 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $414.42 | 2020-2025 | Breztri, Farxiga |
| Acorda Therapeutics, INC | $394.92 | 2020-2024 | Inbrija, Ampyra |
| Biogen, INC. | $387.92 | 2021-2025 | Tysabri, Vumerity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.81 | 2019-2025 | Jardiance |
| Lundbeck LLC | $334.99 | 2020-2025 | Vyepti, Rexulti |
| Avadel Cns Pharmaceuticals, LLC | $327.80 | 2024-2025 | Lumryz |
| Ucb, INC. | $327.35 | 2022-2025 | Cimzia, Nayzilam, Briviact |
| Merz Pharmaceuticals, LLC | $308.93 | 2022-2025 | Xeomin, Ampyra, Inbrija |
| Neurocrine Biosciences, INC. | $305.82 | 2020-2025 | Ongentys, Ingrezza |
| Axsome Therapeutics, INC. | $272.42 | 2022-2025 | Sunosi, Auvelity |
| Lilly USA, LLC | $268.26 | 2021-2025 | Amyvid, Emgality, Kisunla |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helena Sagalovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.